Article

Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma.

2008-04-01

Abstract excerpt

Emerging disease modifying therapeutic strategies for Alzheimer's disease (AD) have generated a critical need for biomarkers of early stage disease. Here, we describe the identification and assessment of a number of candidate biomarkers in patients with mild to moderate probable AD. Plasma from 47 probable Alzheimer's patients and 47 matched controls were analysed by proteomics to define a significant number of pr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b326e264-67f8-52b4-9599-37e72de62ef1
DOI: 10.1002/prca.200780101

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma.DOI 10.1002/prca.200780101Read

Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease.Semantic proximity Read

Discovery of plasma protein biomarkers related to Alzheimer’s disease, sex and APOE genotypeSemantic proximity Read

Translational study of Alzheimer's disease (AD) biomarkers from brain tissues in AβPP/PS1 mice and serum of AD patients.Semantic proximity Read

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.Semantic proximity Read

Reverse engineering of Alzheimer's disease based on biomarker pathways analysis.Semantic proximity Read

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's DiseaseSemantic proximity Read

Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals.Semantic proximity Read

Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.Semantic proximity Read

Feasibility of an early Alzheimer's disease immunosignature diagnostic test.Semantic proximity Read

Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease.Semantic proximity Read

Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer’s diseaseSemantic proximity Read

Plasma proteomic signatures predict dementia and cognitive impairmentSemantic proximity Read